Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Ousseny Zerbo and Nicola Klein.
Ousseny Zerbo
Connection Strength
16.054
Nicola Klein
  1. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024 Jan 09.
    View in: PubMed
    Score: 0.960
  2. Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant. AJOG Glob Rep. 2023 Nov; 3(4):100264.
    View in: PubMed
    Score: 0.935
  3. Individual and neighborhood factors associated with being unvaccinated against COVID-19 among pregnant persons. Hum Vaccin Immunother. 2023 08 01; 19(2):2256042.
    View in: PubMed
    Score: 0.931
  4. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. Nat Commun. 2023 Feb 28; 14(1):894.
    View in: PubMed
    Score: 0.904
  5. Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life. Res Sq. 2022 Oct 18.
    View in: PubMed
    Score: 0.881
  6. Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero. Pediatrics. 2022 07 01; 150(1).
    View in: PubMed
    Score: 0.863
  7. Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine. 2022 Apr 20; 40(18):2568-2573.
    View in: PubMed
    Score: 0.846
  8. Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness. Expert Rev Vaccines. 2021 Oct 08; 1-9.
    View in: PubMed
    Score: 0.821
  9. Population-based assessment of risks for severe COVID-19 disease outcomes. Influenza Other Respir Viruses. 2021 Aug 25.
    View in: PubMed
    Score: 0.814
  10. Individual and Neighborhood Factors Associated With Failure to Vaccinate Against Influenza During Pregnancy. Am J Epidemiol. 2020 11 02; 189(11):1379-1388.
    View in: PubMed
    Score: 0.770
  11. Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time. Hum Vaccin Immunother. 2020 12 01; 16(12):3098-3102.
    View in: PubMed
    Score: 0.745
  12. Parental risk factors for fever in their children 7-10 days after the first dose of measles-containing vaccines. Hum Vaccin Immunother. 2020 04 02; 16(4):875-880.
    View in: PubMed
    Score: 0.719
  13. Acellular Pertussis Vaccine Effectiveness Over Time. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.698
  14. Factors Affecting Vaccination in Children and Their Siblings After Autism Spectrum Disorder Diagnosis-Reply. JAMA Pediatr. 2018 Oct 01; 172(10):985-986.
    View in: PubMed
    Score: 0.666
  15. Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings. JAMA Pediatr. 2018 May 01; 172(5):469-475.
    View in: PubMed
    Score: 0.647
  16. Use of acellular pertussis vaccines in the United States: can we do better? Expert Rev Vaccines. 2017 12; 16(12):1175-1179.
    View in: PubMed
    Score: 0.624
  17. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.229
  18. Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. J Infect Dis. 2023 Jan 23.
    View in: PubMed
    Score: 0.224
  19. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
    View in: PubMed
    Score: 0.216
  20. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.211
  21. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 Sep 08.
    View in: PubMed
    Score: 0.204
  22. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021 Sep 03.
    View in: PubMed
    Score: 0.204
  23. Genetic associations with a fever after measles-containing vaccines. Hum Vaccin Immunother. 2021 06 03; 17(6):1763-1769.
    View in: PubMed
    Score: 0.194
  24. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020; 15(2):e0229279.
    View in: PubMed
    Score: 0.183
  25. Influenza Vaccination in the First Trimester of Pregnancy and Risk of Autism Spectrum Disorder-Reply. JAMA Pediatr. 2017 06 01; 171(6):601-602.
    View in: PubMed
    Score: 0.152
  26. No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 05 31; 35(24):3186-3190.
    View in: PubMed
    Score: 0.151
  27. Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder. JAMA Pediatr. 2017 Jan 02; 171(1):e163609.
    View in: PubMed
    Score: 0.148
  28. Kaiser Permanente Northern California pregnancy database: Description and proof of concept study. Vaccine. 2016 11 04; 34(46):5519-5523.
    View in: PubMed
    Score: 0.145
  29. Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. Obstet Gynecol. 2023 09 01; 142(3):636-639.
    View in: PubMed
    Score: 0.058
  30. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.057
  31. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.057
  32. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.056
  33. Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022. J Infect Dis. 2022 Nov 23.
    View in: PubMed
    Score: 0.055
  34. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1335-1342.
    View in: PubMed
    Score: 0.055
  35. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 10 03; 379:e072141.
    View in: PubMed
    Score: 0.055
  36. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.055
  37. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
    View in: PubMed
    Score: 0.054
  38. Safety of COVID-19 Vaccination in US Children Ages 5-11 Years. Pediatrics. 2022 May 18.
    View in: PubMed
    Score: 0.054
  39. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.053
  40. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.053
  41. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.052
  42. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.052
  43. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.052
  44. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.052
  45. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.050
  46. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021; 12:20420986211021233.
    View in: PubMed
    Score: 0.050

© 2024 Kaiser Permanente